Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 3

1(20.0%)

N/A

1(20.0%)

5Total

Phase 4(3)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT03753347Phase 4Active Not Recruiting

TITRE III: Influenza B Immunogenicity Investigation

Role: collaborator

NCT06133400Not ApplicableCompleted

Mapping the Health Status of the Population of French Polynesia: the MATAEA Project

Role: collaborator

NCT02009800Phase 3Completed

ICI-VPH: Impact of HPV Immunisation Schedules Against HPV

Role: collaborator

NCT02237027Phase 4Completed

Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin

Role: collaborator

NCT01467037Completed

Vaccine Effectiveness of RV1 in a Naïve Population

Role: collaborator

NCT02142491Completed

Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in a Population Allergic to Eggs

Role: collaborator

NCT00169858Phase 4Completed

Long Term Immunogenicity Study of Engerix-B Vaccine in 10 Year Old Children and the Effect of Booster Injections

Role: collaborator

NCT01318876Completed

Surveillance for Adverse Events Following Influenza Immunization

Role: collaborator

NCT01289418Completed

Surveillance for Adverse Events Following Pandemic H1N1 Immunization

Role: collaborator

NCT01247415Unknown

Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine

Role: collaborator

All 10 trials loaded